The world's first clinical trial designed to explore using a hallucinogen from magic mushrooms to treat people with depression has stalled because of British and European rules on the use of illegal drugs in research.
David Nutt, president of the British Neuroscience Association and professor of neuropsychopharmacology at Imperial College London, said he had been granted an ethical green light and funding for the trial, but regulations were blocking it.
"We live in a world of insanity in terms of regulating drugs," he told a neuroscience conference in London on Sunday.Read more »
The hallucinogen psilocybin -- known by the street name magic mushrooms -- may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.Read more »
LIVE 7 Days a Week!
Mon-Sun: 7pm-10pm Eastern